Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the target of a large growth in short interest in August. As of August 31st, there was short interest totaling 117,132 shares, a growth of 90.7% from the August 15th total of 61,410 shares. Based on an average daily volume of 34,578 shares, the days-to-cover ratio is presently 3.4 days. Approximately 0.3% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Estrella Immunopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Estrella Immunopharma Stock Up 4.7%

Shares of Estrella Immunopharma stock traded up $0.03 on Wednesday, reaching $0.64. 45,210 shares of the stock were exchanged, compared to its average volume of 100,411. The business has a 50 day moving average price of $0.74 and a two-hundred day moving average price of $1.05. The firm has a market capitalization of $27.84 million, a price-to-earnings ratio of -2.67 and a beta of 0.88. Estrella Immunopharma has a twelve month low of $0.58 and a twelve month high of $3.15.

Estrella Immunopharma (NASDAQ:ESLA) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.04. Research analysts forecast that Estrella Immunopharma will post -0.25 EPS for the current year.

Institutional Trading of Estrella Immunopharma

An institutional investor recently bought a new position in Estrella Immunopharma stock. BlackRock Inc. bought a new stake in shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 52,033 shares of the company’s stock, valued at approximately $54,000. BlackRock Inc. owned 0.12% of Estrella Immunopharma at the end of the most recent reporting period. 0.35% of the stock is currently owned by institutional investors.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.